Elekta Investor Presentation — February 2020

Document content

Outlook maintained for the full -year

February 20, 2020Agenda

Important information

This presentation includes forward -looking statements including, but not limited to, statements relating to

operational and financial performance, market conditions, and other similar matters. These forward -

looking statements are based on current expectations about future events. Although the expectations

described in these statements are assumed to be reasonable, there is no guarantee that such forward -

looking statements will materialize or are accurate. Since these statements involve assumptions and

estimates that are subject to risks and uncertainties, results could differ materially from those set out in

the statement. Certain of these risks and uncertainties are described further in the Annual Report in

section “Risks and uncertainties”. Elekta undertakes no obligation to publicly update or revise any

forward -looking statements, whether as a result of new information, future events or otherwise, except as

required by law or stock exchange regulations.

This presentation is intended for investors and analysts only. Some products are still in research and/or

not cleared/approved in all markets. Cancer statistics are given to show the potential market in the

respective area and does not mean that Elekta currently has products to treat these indications.

Dr. Richard Hausmann

Everyone with cancer should

have access to and benefit

from precise, personalized

radiotherapyMedicine.Radiation.Precision.

Driving innovation and thought leadership

MR-Linac paradigm shift

•Elekta Unity superior high -field system

•Excellent clinical results from 20 Elekta